Banning prior authorization for buprenorphine has not kept more patients in treatment

Fewer than one in three patients starting buprenorphine for opioid use disorder stays on the medication for six months. That number did not budge in states that banned the insurance practice of requiring prior authorization for the drug, according to a study published March 6, 2026, in JAMA Health Forum.

The finding complicates a popular policy strategy. Over the past several years, 19 states have enacted laws prohibiting private insurers from requiring prior authorization for buprenorphine, the leading medication for opioid use disorder. The logic was straightforward: prior authorization creates delays and interruptions that disrupt treatment, so removing it should help patients stay on their medication longer. But according to the data, it has not worked that way.

What prior authorization does

Prior authorization is an administrative process in which insurance companies require approval before covering a treatment. For buprenorphine, this can mean waiting to start therapy, delays in refilling prescriptions, or interruptions when switching formulations. Approvals are typically granted for limited durations, so even patients who successfully start treatment may face repeated bureaucratic hurdles.

For a medication that relieves opioid cravings and withdrawal symptoms, any delay can be dangerous. Patients who cannot access their medication are at heightened risk of relapse and overdose. Despite the largest annual decrease in overdose deaths since 2019 during the 2023-2024 period, nearly 55,000 people still died from opioid overdose in 2024.

The study

Senior author Dr. Yuhua Bao and her team at Weill Cornell Medicine analyzed data from approximately 23,000 patients aged 18 to 64 who started new buprenorphine treatments between January 2015 and June 2022. During this period, 19 states implemented laws banning private insurance prior authorization for the drug.

The primary outcome was whether patients remained on buprenorphine for at least 180 days without gaps exceeding seven days. By that measure, only 30.4% of patients across the study succeeded. Even with a more lenient definition allowing gaps of up to 30 days, fewer than half (45.7%) stayed in treatment.

Patients in states with prior authorization bans did not show statistically significant improvement in retention compared to patients in states without such laws.

Why removing one barrier is not enough

The results suggest that prior authorization is only one of many obstacles between patients and sustained buprenorphine treatment. Other barriers documented in the literature include requirements for drug testing as a condition of continued prescriptions, mandatory counseling that some patients cannot access, quantity limits on medication, an insufficient number of prescribing providers, and persistent stigma surrounding medication-assisted treatment for addiction.

There is also the question of enforcement. Laws banning prior authorization do not necessarily mean insurers comply fully. Without robust monitoring and enforcement mechanisms, insurers may use other administrative tools to achieve similar gatekeeping effects. Step therapy requirements, formulary restrictions, and quantity limits can all function as de facto prior authorization under different names.

Policy implications

The study does not argue that prior authorization bans are misguided. Removing administrative barriers to life-saving medication remains a reasonable policy goal. But the findings suggest that these laws alone are insufficient to solve the treatment retention problem.

The authors point to a need for complementary interventions: expanding the number of providers who prescribe buprenorphine, reducing stigma around medication-assisted treatment, improving access to counseling and recovery services, and ensuring that insurer compliance with existing laws is monitored and enforced.

First author Dr. Allison Ju-Chen Hu, now at Tulane University, emphasized that legislative bans on prior authorization may have limited impact without these supporting measures.

The broader picture

Buprenorphine treatment retention rates of 30% are a systemic failure, not merely a policy one. The 180-day benchmark is not arbitrary; it represents the minimum treatment duration recommended by clinical guidelines to substantially reduce the risk of relapse, overdose, and death. That seven out of ten patients fall short, regardless of their state's prior authorization policies, indicates that the barriers to successful opioid use disorder treatment are deeply structural.

The opioid crisis has killed over half a million Americans since 1999. Tools to address it exist, buprenorphine chief among them. The challenge is not just making the medication available but creating the conditions under which patients can actually use it long enough for it to work.